- Home
- ZLAB vs AMRX Comparison
ZLAB vs AMRX Comparison
Compare ZLAB & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- AMRX
- Stock Information
- Founded
- ZLAB 2013
- AMRX 2002
- Country
- ZLAB China
- AMRX United States
- Employees
- ZLAB N/A
- AMRX N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- AMRX Biotechnology: Pharmaceutical Preparations
- Sector
- ZLAB Health Care
- AMRX Health Care
- Exchange
- ZLAB Nasdaq
- AMRX Nasdaq
- Market Cap
- ZLAB 3.2B
- AMRX 3.7B
- IPO Year
- ZLAB 2017
- AMRX N/A
- Fundamental
- Price
- ZLAB $20.98
- AMRX $11.62
- Analyst Decision
- ZLAB Buy
- AMRX Buy
- Analyst Count
- ZLAB 6
- AMRX 3
- Target Price
- ZLAB $57.22
- AMRX $12.67
- AVG Volume (30 Days)
- ZLAB 899.6K
- AMRX 1.8M
- Earning Date
- ZLAB 11-06-2025
- AMRX 10-30-2025
- Dividend Yield
- ZLAB N/A
- AMRX N/A
- EPS Growth
- ZLAB N/A
- AMRX N/A
- EPS
- ZLAB N/A
- AMRX 0.02
- Revenue
- ZLAB $441,629,000.00
- AMRX $2,934,959,000.00
- Revenue This Year
- ZLAB $40.71
- AMRX $10.20
- Revenue Next Year
- ZLAB $50.42
- AMRX $6.95
- P/E Ratio
- ZLAB N/A
- AMRX $719.66
- Revenue Growth
- ZLAB 24.14
- AMRX 9.50
- 52 Week Low
- ZLAB $20.61
- AMRX $6.69
- 52 Week High
- ZLAB $44.34
- AMRX $12.12
- Technical
- Relative Strength Index (RSI)
- ZLAB 21.54
- AMRX 62.95
- Support Level
- ZLAB $21.59
- AMRX $11.44
- Resistance Level
- ZLAB $22.28
- AMRX $12.12
- Average True Range (ATR)
- ZLAB 0.86
- AMRX 0.45
- MACD
- ZLAB -0.18
- AMRX 0.03
- Stochastic Oscillator
- ZLAB 6.41
- AMRX 77.23
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.